PD-1 inhibitors, such as pembrolizumab, have achieved significant efficacy in treating a range of malignancies, including NSCLC, melanoma, and hodgkin lymphoma (HL) [120]. Here, PDCD1 is linked to non-small cell lung carcinoma.